Shabani Samira, Khayer Nasibeh, Motalebzadeh Jamshid, Majidi Zadeh Tayebeh, Mahjoubi Frouzandeh
Department of Clinical Genetic, National Institute of Genetic Engineering and Biotechnology (NIGEB), Tehran, Iran.
Skull Base Research Center, The Five Senses Health Institute, Iran University of Medical Sciences, Tehran, Iran.
Gastroenterol Hepatol Bed Bench. 2021 Spring;14(2):123-131.
Efforts to explore biomarkers and biological pathways involved in the disease are needed to improve colorectal cancer (CRC) diagnosis and alternative treatments.
The fourth common malignancy in the world is colorectal cancer. The over-all burden is predicted to rise by 2030.
In the current study, nine genes were selected. Previously, a panel of genes by Agendia, a classifier of robust gene expression (ColoPrint), was determined to significantly improve the prognostic accuracy of pathologic factors in stage II and III colorectal cancer patients. Five genes, including , and from this panel and four other genes which were not in this panel but were cited abundantly in the literature were selected. Then, expression levels of the selected genes in CRC tissue were compared with levels in adjacent normal tissue. To identify the pathways involved in CRC, gene set enrichment analysis was subsequently performed. Furthermore, to illustrate the relationship between genes in this disease, the cross-shaped co-expression pattern and gene regulatory network were determined using computational methods.
This research found that the pairs of genes: {}, {, }, {}, and {} are functionally related. Furthermore, two differentially expressed gene pairs ({} and {}) are involved in the vascular endothelial growth factor receptor signaling pathway and the purine ribonucleoside diphosphate metabolic process, respectively.
This research found that the combination of computational analysis and laboratory data provided the opportunity to better characterize the relation between central colorectal cancer genes as well as possible pathways involved in the colorectal cancer.
需要努力探索与该疾病相关的生物标志物和生物学途径，以改善结直肠癌（CRC）的诊断和替代治疗方法。
结直肠癌是世界上第四大常见恶性肿瘤。预计到2030年，其总体负担将会增加。
在本研究中，选择了9个基因。此前，Agendia公司的一组基因（一种强大的基因表达分类器，ColoPrint）被确定能显著提高II期和III期结直肠癌患者病理因素的预后准确性。从该组中选择了5个基因，包括 、 和 ，以及另外4个不在该组但在文献中被大量引用的基因。然后，将所选基因在CRC组织中的表达水平与相邻正常组织中的水平进行比较。为了确定参与CRC的途径，随后进行了基因集富集分析。此外，为了阐明该疾病中基因之间的关系，使用计算方法确定了十字形共表达模式和基因调控网络。
本研究发现基因对：{}、{, }、{}和{}在功能上相关。此外，两个差异表达基因对（{}和{}）分别参与血管内皮生长因子受体信号通路和嘌呤核糖核苷二磷酸代谢过程。
本研究发现，计算分析与实验室数据相结合，为更好地表征结直肠癌核心基因之间的关系以及结直肠癌可能涉及的途径提供了机会。
